poisar

Stocks · News reference

Bristol Myers Squibb Reports Third Quarter 2026 Financial Results

Bristol Myers Squibb released its financial results for the third quarter of 2026 on October 29, 2026.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BMY
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. David Kretzmann

    Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

    Bristol Myers Squibb's Growth Portfolio of newer drugs surged 12% to $7.7 billion in Q3 2026, driving the company's 7% overall revenue growth to $13.1 billion. While adjusted EPS fell 17% to $1.35, this decline reflects upfront acquisition costs for pipeline drugs rather than core business weakness. The company raised its 2026 revenue guidance to $49.75-$50.25 billion, signaling confidence in its drug portfolio diversification strategy.

    BMYCELGR
  3. Benzinga Insights

    Bristol-Myers Squibb Q3 2026 Earnings Call Transcript

    Bristol-Myers Squibb (NYSE:BMY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga

    BMY